What question did this study set out to answer?

The aim is to correct inaccuracies found in previously published tables regarding treatment data.

July 8, 2026Nature Medicine0 citationsOpen Access

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

MRMarc S. RaabGerman Cancer Research Center NWNiels WeinholdGerman Cancer Research Center KKK. Martin KortümUniversitätsklinikum Würzburg

Key Points

The aim is to correct inaccuracies found in previously published tables regarding treatment data.
Correction of typographical errors in Table 2 and Table 3.
Updated HTML and PDF versions of the article reflect these corrections.
Table 2, row 1, column 5 corrected from '19 (95.0)' to '20 (100)'.
Table 3, row 1, column 6 corrected from '11 (57.9)' to '12 (63.2)'.
Table 3, row 1, column 8 corrected from '39 (79.6)' to '40 (81.6)'.

Abstract

In the version of this article initially published, there was a typographical error in Table 2, row 1, column 5, where “20 (100)” appeared originally as “19 (95.0)” and errors in Table 3, row 1, column 6, where “12 (63.2) appeared originally as “11 (57.9)” and in row 1, column 8, where “40 (81.6)” appeared originally as “39 (79.6).” The tables are now amended in the HTML and PDF versions of the article.

KI fragen

Bookmark

View Full Paper